Osteoarthritis and Cartilage

OARSI OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL

Review

Three decades of advancements in osteoarthritis research: insights from transcriptomic, proteomic, and metabolomic studies

Muhammad Farooq Rai # [1], Kelsey H. Collins † [1], Annemarie Lang ‡ [1], Tristan Maerz § [1], Jeroen Geurts ¶ [1], Cristina Ruiz-Romero ‖ [1], Ronald K. June ## [1], Yolande Ramos †† [1], Sarah J. Rice ‡‡ [1], Shabana Amanda Ali §§ [1], Chiara Pastrello ¶¶ [1], Igor Jurisica ¶¶ ‖‖ [1], C. Thomas Appleton ### [1], Jason S. Rockel ¶¶ [1], Mohit Kapoor ¶¶ * [1]

Department of Anatomy and Cellular Biology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
† Department of Orthopaedic Surgery, University of California San Francisco, San Francisco, CA, USA
‡ Departments of Orthopaedic Surgery and Bioengineering, University of Pennsylvania, Philadelphia, PA, USA
§ Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA
¶ Rheumatology, Department of Musculoskeletal Medicine, Lausanne University Hospital, Lausanne, Switzerland
‖ Grupo de Investigación de Reumatología (GIR), Unidad de Proteómica, INIBIC –Hospital Universitario A Coruña, SERGAS, Spain
Department of Mechanical & Industrial Engineering, Montana State University, Bozeman, MT, USA
†† Dept. Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands
‡‡ Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
§§ Henry Ford Health + Michigan State University Health Sciences, Detroit, MI, USA
¶¶ Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, UHN, Toronto, ON, Canada
‖‖ Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, ON, Canada
Department of Medicine, University of Western Ontario, London, ON, Canada

ARTICLE INFO

SUMMARY

Objective: Osteoarthritis (OA) is a complex disease involving contributions from both local joint tissues and systemic sources. Patient characteristics, encompassing sociodemographic and clinical variables, are intricately linked with OA rendering its understanding challenging. Technological advancements have allowed for a comprehensive analysis of transcripts, proteomes and metabolomes in OA tissues/fluids through omic analyses. The objective of this review is to highlight the advancements achieved by omic studies in enhancing our understanding of OA pathogenesis over the last three decades.
Design: We conducted an extensive literature search focusing on transcriptomics, proteomics and metabolomics within the context of OA. Specifically, we explore how these technologies have identified individual transcripts, proteins, and metabolites, as well as distinctive endotype signatures from various body tissues or fluids of OA patients, including insights at the single-cell level, to advance our understanding of this highly complex disease.
Results: Omic studies reveal the description of numerous individual molecules and molecular patterns within OA-associated tissues and fluids. This includes the identification of specific cell (sub)types and associated pathways that contribute to disease mechanisms. However, there remains a necessity to further advance these technologies to delineate the spatial organization of cellular subtypes and molecular patterns within OA-afflicted tissues.
Conclusions: Leveraging a multi-omics approach that integrates datasets from diverse molecular detection technologies, combined with patients' clinical and sociodemographic features, and molecular and regulatory networks, holds promise for identifying unique patient endophenotypes. This holistic approach can illuminate the heterogeneity among OA patients and, in turn, facilitate the development of tailored therapeutic interventions.

* Correspondence to: 60 Leonard Avenue, 5th Floor Krembil Discovery Tower, Toronto, Ontario, Canada.
  E-mail address: mkapoor@uhnresearch.ca (M. Kapoor).
[1] All authors contributed equally.

Introduction

Osteoarthritis (OA) is characterized by pain and reduced function, involving both local joint and systemic tissues and fluids. Various sociodemographic and clinical factors are associated with incidence and progression of OA.[1,2] These sociodemographic (e.g., age, sex, BMI etc.) and clinical factors (e.g., chronic pain, comorbidities such as metabolic disorders, inflammation, malalignment etc.) refer to some phenotypes of OA. Studies have described multiple OA phenotypes, with contributions of these components.[3,4] Individual patient characteristics can also modify systemic molecular profiles,[5] contributing to OA. OA endotypes are defined by molecular signatures and associated mechanisms that underly disease pathologies. For instance, low tissue turnover, structural damage, and systemic inflammation endotypes were identified from biochemical markers in urine and serum using two prospective cohorts of patients with OA, with some differences in the proportions of subjects with pain and structural progression between endotype groups.[6] However, all groups had progressors and non-progressors regardless of group, suggesting the biochemical marker endotypes identified are only part of the puzzle. A deeper understanding OA endotypes has recently become a major focus to uncover new targets and disease-associated mechanisms. This is achieved through advanced omic technologies, including transcriptomics, proteomics, and metabolomics. Combining endotypes uncovered from these advanced approaches with OA patient phenotypes may help to uncover distinct endotype-phenotype combinations (endophenotypes) to disentangle OA disease heterogeneity.

Transcriptomics analyzes transcripts expressed from the genome.[7] Proteomics, conceived in 1994,[8] is the large-scale analysis of proteins, including their identification, quantification, post-translational modifications (PTMs), localization, and degradation. Metabolites are the reactants and products of biochemical reactions mediated by proteins. Metabolomics, defined in 1998,[9] involves the characterization of thousands of metabolites.[10]

Over the past 30-plus years, advancements in transcriptomics, proteomics, and metabolomics technologies have provided insight into molecular changes occurring in OA tissues and fluids. In this review, we highlight how these omic technologies have contributed to our biological understanding of OA. We also discuss how spatial-omics could aid in better understanding OA at the tissue level, and how multi-omics approaches can help define OA populations by both endotype and phenotype, unraveling the complex heterogeneity observed in individuals with OA.

Transcriptomics

The field of OA has greatly benefited from high-throughput transcriptomic tools (Fig. 1). Advancements in microarray technologies, followed by progressive improvements to high-throughput sequencing methods, including "bulk" RNA-sequencing (RNA-seq) and single cell (sc)RNA-seq, have led to deeper understanding OA pathophysiology at the tissue, cell, and molecular level. Here, we emphasize the application of transcriptomics in different joint tissues affected by this disease.

Cartilage

In adult articular cartilage tissue, the sole cell type found are chondrocytes that are organized into zones where they have distinct functions to maintain tissue homeostasis and extracellular matrix (ECM) turnover. During OA, there is a shift from homeostasis to catabolism, resulting in cartilage degeneration and loss of chondrocytes.

Early OA studies using DNA array technology focused on disease mechanisms including involvement of matrix metalloproteinases or the imbalance between anabolic and catabolic processes by comparing unaffected and OA-damaged cartilage.[11] More comprehensive microarray studies in the early 2000s reported significant differences in differentially expressed genes related to cell proliferation, collagen synthesis, and ECM degradation when comparing intact and damaged cartilage,[12] and differentiated between different grades of OA cartilage specimens demonstrating the potential implication of increased oxidative stress and cell damage in OA chondrocytes.[13] Following studies tried to tackle specific experimental challenges using genome-wide microarrays and different specimen comparisons.[14–16] As a result, the list of pathologically relevant candidate genes was extended, including genes involved in bone formation and skeletal development.

Since human repair phenotypes are inaccessible and clinical samples are limited for analysis, animal models provide a great opportunity to uncover additional genes and signaling pathways that are regulated at the transcriptional level during early OA. Appleton et al. performed one of the first studies investigating transcriptional changes in chondrocytes using a surgically induced rat OA model[17] and identified chemokines, such as *Cxcr4* and *Ccl2*, with implications in progressing and early degrading cartilage, respectively. Studies in mice undergoing destabilization of the medial meniscus (DMM) surgery to induce OA, aimed to delineate the evolution of changes in chondrocyte gene expression during early disease, focusing on different time-points,[18,19] and dissect the role of previously identified central genes (such as *ADAMTS5*) and aging.[20] These preclinical studies had a crucial role in characterizing the complex pathogenesis of OA cartilage degradation, which is activated upon first disease induction.

It has been proposed to enrich the current, more clinical approaches towards phenotyping to include molecular endotypes derived from omic technology data.[21] Fernández-Tajes et al. found in cartilage microarray data from 23 patients two endotypes with gene expression differences related to inflammatory response,[22] while Soul et al. identified two endotypes in RNA-seq data from 44 patients, but with differences related to oxidative stress, innate immune responses and Wnt signaling.[23] Steinberg et al. reported comparable observations with two endotypes (including inflammation).[24] Yuan et al. identified four patient endotypes when combining different tissues, underlining the importance of OA as a "whole joint disease."[25] Future studies will leverage advanced computational methods and machine learning to characterize transcriptomic endotypes and their correlation with clinical phenotypes.

The first scRNA-seq study on human OA cartilage was published in 2018, providing evidence for seven molecularly-specific subpopulations and transient states of chondrocytes, as well as novel functional phenotypes with regulatory functions including immunomodulation.[26] The dataset further allowed identification of cartilage progenitor cells (CPCs) that express stem cell-related surface markers. Following studies partly confirmed these initial findings and integrated synovial tissue/cells in the analysis to dissect synovial cell-chondrocyte crosstalk mechanisms.[27] These cell population-based studies uncovered subordinate disease mechanisms that have been submerged in RNA-seq gene expression studies, such as ferroptosis.[28] One of the first studies published applying scRNA-seq to animal models was conducted, demonstrating that most cell clusters described in humans are also present in mouse knee cartilage.[29] A recent methodological approach combined RNA-seq with scRNA-seq, which generated a high confidence (pure) chondrocyte gene signature by avoiding cross-contamination from other tissues, a process necessary in smaller animal models with limited tissue availability.[30] These advancements have led to a deeper understanding of molecularly defined chondrocyte subtypes, including the

Fig. 1

Osteoarthritis and Cartilage

Transcriptomics – technological advancements and application to OA. Transcriptomics has evolved over time from the advent of SAGE sequencing and microarrays to include high-throughput sequencing techniques. Combining sequencing technology with microarray and imaging has also allowed for the development of spatial transcriptomics. Transcriptomics has advanced the field of OA by enhancing our understanding of tissue-specific and inter-tissue cross-talk, determination of key genes associated with OA, uncovering transcriptomic endotypes, and identifying joint cell heterogeneity.

differentiation between pre-hypertrophic and hypertrophic chondrocytes, and the definition of CPCs, with more recent studies shedding light into synovial-chondrocyte cell interactions and immune cell involvement in OA cartilage degradation.

Synovium

The synovium is the inner lining of joints. Composed of a heterogeneous population of stromal cells, immune cells, adipocytes, and nerve-, blood vessel-, and lymphatic vessel-associated cells, the synovium undergoes dynamic cellular and molecular changes during OA progression.[31]

Early microarray studies of rodent and human OA synovium revealed a signature of fibroblastic and myeloid enrichment, with regulated genes involved in TGF-β signaling, collagen synthesis and cross-linking, and innate immunity.[32] Relevant to fibrosis, Remst et al. found that *PLOD2*, *LOX*, *COL1A1*, *COL5A1*, and *TIMP1* were increased in end-stage human OA synovial tissue and TGF-β-stimulated human OA synovial fibroblasts.[32] Lambert et al. analyzed human end-stage OA synovium by microarray of normal vs inflamed regions within the same subjects.[33] Inflamed synovial regions overexpressed select cytokines, chemokines, various enzymes, catabolic proteases, and markers of angiogenesis. This was among the first studies to demonstrate anatomic region-dependent variability in the transcriptome of OA synovium. Microarray analysis of

cultured synovial fibroblasts from end-stage OA, compared to healthy and end-stage RA synovial tissue, showed that OA fibroblasts exhibited enriched genes related to cell adhesion and actin cytoskeleton, small GTPases and GTPase signal transduction, and neurotrophic mediators, further solidifying the more fibrotic nature of OA synovium.[34] Microarray studies were instrumental in revealing the synovial gene expression signatures of OA, marked by abundant adaptive immune-related and pro-fibrotic processes.

The advent of RNA-seq facilitated deeper identification of specific signaling pathways active in the OA synovium. Steinberg et al. performed RNA-seq analysis of synovium from 113 OA patients and identified two synovial endotypes: one characterized by inflammatory genes and one by ECM- and cell adhesion-related genes.[35] It is unclear whether these endotypes are simply different disease states (e.g., patients with active inflammatory flares) or truly reflect different pathomechanisms. To study the contribution of beneficial (i.e., exercise) and detrimental (i.e., injury and fibrosis) mechanical loading experienced by synovium, Philpott et al. subjected human late-stage OA synovial tissue to low-frequency or high-frequency tensile strain, followed by RNA-seq.[36] Low-frequency loading enriched for pathways reglated to deinterferon-gamma and -alpha responses, Fc receptor signaling, and lysosomal routing, proposed as protective immunomodulatory and inflammation-resolving functions. Conversely, high-frequency loading activated

pathways related to NOD-like receptor signaling and redox stress, increased lactate release, and promoted 3-nitrotyrosine formation, which are detrimental to synovium as they induce synovial inflammation. Further studies are needed to describe mechanoreceptors and intracellular signaling responsible for synovium mechanosensitivity.

To study macrophage phenotypes in arthritis, flow-sorted synovial tissue-derived macrophages from OA and inflammatory arthritis (RA or psoriatic arthritis) were analyzed by RNA-seq.[37] Two distinct subgroups of OA macrophages were identified, underpinned by 155 differentially-expressed genes: a "classical OA" subset and an "inflammatory-like OA" subset more similar to macrophages from inflammatory arthritis. The inflammatory-like subset was enriched in pro-inflammatory signaling and cell-cycle genes, which was functionally confirmed by flow cytometry, demonstrating that synovial tissue from these patients had a ~2.5-fold greater number of macrophages. Using a model of anterior cruciate ligament (ACL) rupture in mice, Bergman et al. described divergence of synovial transcriptomes between male and female mice associated with greater progression of post-traumatic OA severity, pain behavior, matrixmetalloproteinase activity, and osteophyte formation in male mice.[38] Male mice had increased expression of pro-fibrotic, neuroangiogenic, and extracellular signal-regulated kinase signaling genes, indicating that synovitis may be a key driver of the well-documented greater OA severity in male mice across OA models.

One of the first scRNA-seq datasets of OA synovium was published in 2018, which included characterization of synovial fibroblasts from OA and RA patients.[39] From 337 fibroblasts from two OA and two RA patients, this study identified three primary synovial fibroblast groups: 1) A CD34(-), Thy1(-) population, now recognized as *PRG4*High, *CLIC5*+ lining/intimal fibroblasts; 2) A CD34(-) Thy1(+) population localized to the sublining/subintima near blood vessels, and 3) a CD34(+) Thy1(+), now recognized to represent progenitor-like *DPP4*+/*PI16*+ "universal fibroblasts."[40] The first whole-synovium OA atlas was published by Chou et al. in 2020 and comprised ~10,600 synovial cells from three OA patients.[41] Major synovial cell types were identified and characterized by top differentially expressed genes: lining fibroblasts, sublining fibroblasts, smooth muscle cells, endothelial cells, mast cells, T cells, macrophages, dendritic cells, and B cells. This study also constructed a model of synovial-cartilage crosstalk using ligand-receptor expression patterns, demonstrating that synovium is the primary contributor of cytokines and chemokines whereas cartilage is responsible for growth factor and morphogen production.

To understand cellular sources of neurotrophic mediators responsible for OA pain, Nanus et al. demonstrated that OA synovial tissue from sites of joint pain are enriched in synovial fibroblasts expressing neurotrophic mediators, compared to sites with lesser pain.[42] In end-stage OA patients, these fibroblasts expressed genes related to eicosanoid signaling, prostanoid biosynthesis, and insulin growth factor-1 (IGF-1) signaling, all recognized to mediate nociceptive sprouting and pain perception. In early OA painful synovial sites, fibroblasts also expressed genes related to IGF-1 and eicosanoid signaling. Thus, local enrichment of nociceptive nerve fibers giving rise to region-dependent pain signatures is likely driven, in-part, by distinct synovial fibroblast subsets. Defining the molecular regulation of these fibroblasts could produce novel OA pain therapeutics targeting these cells.

To describe the emergence of post-traumatic OA-associated synovial fibroblasts, Knights et al. performed scRNA-seq of murine synovium following noninvasive ACL rupture.[43] Seven synovial fibroblast subsets were described, including a *Prg4*High lining fibroblast, which overexpressed the Wnt agonist R-spondin 2 following injury, and four sublining fibroblast populations with unique molecular programs. Among the sublining populations was a *Dpp4*+/*Pi16*+ stromal progenitor, consistent with the "universal fibroblast."[40]

Differentiation trajectory analysis suggested this population gave rise to *Acta2*/αSMA+ myofibroblasts that further transitioned into *Prg4*High lining fibroblasts, underpinning synovial lining hyperplasia. *Sox5* was identified as a molecular regulator of *Dpp4*+ progenitor-derived lining fibroblasts and R-spondin 2 expression. Subsequent work using a cartilage injury model further demonstrated that *Dpp4*+/*Pi16*+ synovial progenitors were derived from the *Gdf5*-lineage joint interzone, giving rise to *Prg4*-expressing lining fibroblasts, with *Sox5, Foxo1, and Creb5* predicted as transcription factors underpinning lining fibroblast fate.[44]

Robust descriptions of OA synovial immune phenotypes and their origins are still lacking, which remain challenging given the incomplete understanding of genes unique to synovial immune cells, absence of lineage-tracing models that do not overlap between resident and systemically-derived cells, and the short half-life of many immune cells.

Subchondral bone

Subchondral bone refers to cortical, trabecular and marrow adipose tissue (BMAT) compartments beneath articular cartilage. Advanced OA stages display substantial thickening of the subchondral cortical plate and trabeculae. Changes in the composition of BMAT, referred to as bone marrow lesions (BMLs) are associated with pain and cartilage volume loss. First insights from histopathological studies showed blood vessels and nerves invade the subchondral cortical plate during OA, and there is an elevated presence of macrophages, vascular structures, and osteoclasts in BMAT.[45–49]

Initial transcriptomic investigations into human OA subchondral bone and BMLs were conducted during the early to mid-2000s, utilizing microarray technology.[50–52] A landmark study comparing osteoporotic and OA femoral heads yielded initial molecular evidence for increased expression of pro-angiogenic genes within OA subchondral bone.[50] Functional analyses unveiled enrichment of pathways related to angiogenesis, collagen fibrils, and cell proliferation between sclerotic and non-sclerotic tibial plateaus.[53] A similar approach comparing knee tibia BMLs to controls identified angiogenesis, cytokine signaling, PDGF and Wnt signaling pathway enrichment.[52] Among the potential molecular targets suggested by these studies, *STMN2, IL11* and *CHADL* were confirmed recently using RNA-Seq.[54]

Advancements in bioinformatic tools have helped to start unravel cellular and molecular mechanisms driving tissue remodeling in OA. Ligand-receptor mapping of cartilage and subchondral bone RNA-seq profiles inferred increased angiogenesis and ECM remodeling pathway molecular crosstalk.[25] However, the diverse array of cell types present in subchondral bone, including osteocytes, adipocytes, osteoblasts, osteoclasts, vascular cells, immune cells, and progenitor cells in BMAT, continues to present significant challenges in interpreting bulk transcriptomics data. Notably, a preliminary study utilizing scRNA-seq indicated the existence of at least 10 distinct molecular cell types within BMAT.[55]

The size of murine joints is a major constraint to study subchondral bone in models of OA, thus transcriptomic analyses were usually conducted using intact cartilage and bone,[56] entire bones,[57] or larger animal models.[58] Analysis of temporal gene expression profiles following surgical induction of OA revealed upregulation of osteoclast-related genes at early stages, followed by induction of osteoblast-related genes at later stages.[58] Furthermore, transcriptomic analysis of aging bone lacking BMAT revealed differential expression of several genes associated with human hip or knee OA, such as *COL27A1, COL2A1* and *COL11A1*.[57]

Expanding upon the foundation laid by current transcriptomic datasets, further investigations using proteomics[59–61] and lipidomics of subchondral bone will open new avenues for disease endotyping, biomarker discovery and development of novel therapeutic targets.

Meniscus

Within OA-affected menisci, there are indications of gross and histologic pathology, characterized by increased water, proteoglycan, and collagen content, and elevated expression of *MMP13*.[62] In a significant advancement, Brophy et al. performed RNA-seq analysis on meniscus tissue, demonstrating that menisci of OA-afflicted joints exhibit an inflammatory phenotype, contrary to menisci from non-OA joints, which display a repair-oriented phenotype.[63] In addition, this analysis revealed the involvement of epigenetically regulated histone deacetylation in meniscus tears as well as the expression of lncRNAs. A subsequent investigation elucidated key biological processes (inflammation, chemotaxis, cytokine-to-cytokine interaction) in the context of OA-related meniscus degradation.[64]

Subsequently, a pioneering scRNA-seq study of human meniscus identified cellular heterogeneity and changes in the proportions of cell clusters based on disease status. In the context of healthy menisci, five empirically defined cell populations and two novel cell clusters were identified. In stark contrast, OA degenerated menisci revealed four cell clusters, with one being distinctive due to its progenitor cell characteristics.[65] In-depth analyses clarified the cellular composition of the meniscus and the precise manners in which specific cell clusters partake in both development and degenerative processes. For instance, gene transcripts representative of meniscus degeneration (*GAS1*, *RAB3B* and *CD318*) were highly expressed in a unique cell cluster. The peak expression of these genes coincided with advanced stages of meniscus cell differentiation, highlighting an aberrant cellular degenerative response, shedding light on potential mechanisms driving meniscus degeneration and its association with OA progression.

Thus, scRNA-seq data augmented our understanding of the spatiotemporal landscape of meniscus gene expression and furnished additional insights into degenerative mechanisms, cellular compositions, and biological links between meniscus tear and OA. Moving forward, investigations that continue this trajectory hold promise to uncover rare meniscus cell subpopulations and improve our understanding of cell-cell interactions within the microenvironment of this clinically-critical tissue and its participation in OA genesis.

Proteomics

Proteomic analyses in OA started in ~2004, yet studies were constrained by technical limitations, especially regarding sensitivity and throughput (Fig. 2). The first proteomic study of osteoarthritic chondrocytes was performed by two-dimensional gel electrophoresis.[66] Since then, strategies using nano-liquid chromatography-mass spectrometry (LC-MS)/MS are most common. By these means, shotgun proteomics studies have elucidated the molecular composition of articular cartilage and other joint tissues. One of the most exhaustive works in this area characterized the different layers of cartilage from healthy or OA hip and knee tissues,[67] identifying more unique proteins in the superficial layer than in the deep one, such as gelsolin, tenascins or lubricin. This study also showed differences in protein abundance related with the disease state (i.e., decrease of COMP or clusterin) or joint site (i.e., aggrecan core protein or matrilin-3 enriched in hip cartilage, while Chitinase-3-like protein 1 or MMP1 increased in the knee tissue). Most recently, cutting-edge technology combining cytometry with mass spectrometry (mass cytometry) allowed single-cell proteomic analyses in cartilage. A panel of 33 markers was developed for profiling chondrocytes by Cytometry by Time of Flight (CyTOF), which was employed to establish a single-cell atlas for cartilage and revealed "rare" cell populations in the OA tissue.[68] This technology has been subsequently used to map the effects of two DMOAD candidates on chondrocytes isolated from patients with end-stage OA.[69] Altogether, single-cell proteomic analysis has shown a great


Fig. 2   Osteoarthritis and Cartilage

Proteomics – technological advancements and applications to OA. Proteomics was originally defined in 1994. Technologies have evolved and include mass spectrometry- and affinity-based techniques for high-throughput, targeted, and single cell proteomics. Beginning in 2004, proteomics research in OA has been used to study protein levels, key enriched pathways, and patient endotypes from multiple joint tissues and synovial fluid.

potential for patient stratification in OA, which may be critical in determining precision medicine approaches.

Other proteomic studies focused exclusively on proteins released (secretome) by articular chondrocytes and cartilage. One of the first works following this reasoning used an in vitro model of bovine cartilage explants to analyze proteins released in response to treatment with IL-1β, TNF-α, or mechanical compression.[70] The cytokine treatment caused a decrease in the synthesis of collagen subunits, and increased release of aggrecan and proteins related to innate immunity, while mechanical compression particularly enhanced the release of intracellular proteins. In another study, secretomes of lesioned and non-lesioned OA human cartilage, and healthy tissue, were compared leading to the identification of proteins distinctively released, such as osteoprotegerin and periostin.[71] Synovial fluid and serum from OA patients have also been analyzed by LC-MS/MS in proteomics as ideal sources for OA biomarkers. The first in-depth study of the OA synovial fluid proteome was published in 2014.[72] Thereafter, several papers searched this proteome to find markers of early OA.[73] A recent study defined a panel of 15 serum proteomic markers to predict OA progression,[74] including peptides from cartilage acidic protein 1 (CRTAC1), vitamin D binding protein and the complement C1r subcomponent.

Global analysis of specific PTMs has also been explored in OA research. A N-glycome analysis of OA chondrocytes and synoviocytes described an increased binding of galectins due to glycoprotein modifications, which induced proinflammatory markers.[75] Another study compared changes in N-glycosylated protein abundance in OA cartilage and controls with traumatic joint injury, identifying 22 N-glycosylated peptides that were increased in the diseased tissues.[76] In another work, Dong and colleagues performed a phosphoproteomic analysis comparing lesioned vs control OA cartilages, identifying > 4000 differential phosphorylated peptides and illustrating alteration of kinase hubs and transduction pathways in OA.[77]

Notably, ECM protein degradation studies have also been in the spotlight of proteomics. Progression of matrix degradation in response to mechanical damage and cytokine treatment in human tissues was explored by targeted proteomics to measure certain protein domains of collagen, aggrecan and COMP.[78] A further study carried out an analysis of endogenous peptides released from human OA cartilage, identifying specific peptides from prolargin and clusterin that were differentially released from OA knee and hip tissues, respectively, compared to healthy.[79] Finally, recent papers in this area described the massive proteolytic events that take place in OA cartilage, delineating the role of specific proteases such as HtrA1.[80]

Affinity proteomics studies have also been carried out for the discovery or OA biomarkers in body fluids. Novel, large-scale affinity proteomics platforms have been developed to facilitate biomarker discovery and risk prediction, including the aptamer-based SomaScan platform (SomaLogic, Boulder, CO) and the proximity extension assay developed by Olink (Uppsala, Sweden). Using SomaScan, 4792 proteins were measured in plasma of > 37,000 individuals to search for potential protein biomarkers of hip, knee, and/or hand OA, and identify biomarkers for joint replacement.[81] CRTAC1 was found to be the most promising candidate biomarker for OA incidence and was predictive of progression to joint replacement. In two recent studies using the Olink platform, CRTAC1 was also strongly associated with OA severity and progression in a screening of Rotterdam study participants,[82] with its predictive nature validated in a study on > 54,000 individuals from the UK Biobank.[83]

Technological advances in affinity proteomics and CyTOF platforms, along with the exceptional capacity of LC-MS/MS to identify protein fragments and modifications with increasing sensitivity and speed, demonstrates that after 20 years of research, proteomics has reached a high level of maturity in the OA field that turns it into the best tool for large-scale functional research in OA.

Metabolomics

The first reports of metabolomics in OA used nuclear magnetic resonance (NMR)-based metabolomics and meniscectomized guinea pigs.[84] NMR also characterized synovial fluid from various joint diseases, finding similarity between metabolomic profiles from OA, RA, crystal-associated arthritis, and spondylarthritis compared to septic arthritis.[85] NMR-based metabolomic profiling of urine distinguished progressors from non-progressors, finding key discriminatory roles for N-N-dimethylglycine, hippurate, histidine, and trigonelline at 18 months.[86] Several studies used MS to study metabolites in OA. The first MS-based metabolomics study targeted 163 metabolites in serum of knee OA subjects and controls, finding ratios of valine to histidine and xleucine (both leucine and iso-leucine) to histidine significantly different between the groups.[87] In infrapatellar fat pad, lipoxin A_4, thromboxane B_2, and arachidonic acid were key metabolites separating OA from normal tissue by dimensionality reduction.[88]

Metabolomic profiling can analyze OA cultured samples and conditioned media. 13-C labeling of carbon sources showed that OA chondrocytes use the tricarboxylic acid cycle, and patient-matched chondrocytes from OA regions produce more lactate than those from macroscopically normal cartilage.[89] Untargeted metabolomic profiling found extracellular stiffness impacts OA chondrocyte mechanotransduction,[90] suggesting that decreased pericellular matrix stiffness may affect OA pathophysiology. In vivo studies support metabolic changes as altered joint mechanotransduction. For example, a single night of wheel exercise induced multiple pathways including amino acid metabolism and synthesis of catecholamines and ubiquinol.[91] Six months of exercise resulted in increased connectivity between local joint-level structural and pathological measures and synovial fluid metabolites.[92] Germ-free mice had decreased variability in synovial fluid metabolomic profiles compared to conventional mice, and in response to joint injury, with metabolite differences related to inflammation and innate immunity.[93] Isotopic labeling in a rat injury model identified potential plasma metabolite biomarkers 2-aminoadipic acid, GABA, and saccharopine.[94] Rats subjected to either high-fat diet or surgical cartilage damage exhibited differences in multiple oxylipins in plasma and synovial fluid.[95] These in vitro and in vivo studies show that metabolomic profiling provides deep insight into OA pathologies, identifies novel disease mechanisms, and finds potential drug targets.

Metabolomic profiling of clinical samples provides detailed insight into the molecular nature of OA. Metabolomic profiles of synovial fluid discriminated between early- and late-stage OA KL grades.[96] Similarly, analysis of post-mortem synovial fluid found distinct endotypes within both early- and late-stage OA.[97] Additional endotypes were discovered by clustering analysis of targeted metabolomic profiles from plasma of OA patients and normal controls.[98] Targeted metabolomic profiling found endotypes within a population of late-stage (KL grades 3–4) OA patients, with key metabolites related to tRNA acylation and B-vitamin metabolism.[99] Targeted metabolomic profiling of plasma from total joint replacement patients found ratios of acetycholine to phosphatidylcholine and phosphatidylcholine-diacyl-C36:4 to isoleucine were associated with post-replacement pain.[100] 1H NMR metabolomics found differences in profiles between inflammatory and fibrotic synovial tissues, as well as correlations between some metabolites detected between synovium and synovial fluid.[101] As technology and biobanks of OA tissues and fluids improve, opportunities to advance human OA research using metabolomic profiling will emerge.

A major challenge of metabolomics is variability (owing in part to dietary and environmental factors) that is hard to control in clinical studies, complicating interpretation of how metabolomic profiles relate to fundamental biology of OA. However, when profiled sequentially in time, metabolite data can provide *bona fide* information for enzymatic activity across multiple pathways simultaneously. Therapeutic interventions can be evaluated through changes in metabolites and metabolomic profiling, which has potential to provide insight into disease endotypes to improve our knowledge of OA and move toward improved clinical treatments.

Spatial-omics

While it has been long appreciated that the articular joint is an organ system,[102] it has been challenging to decode the factors that govern inter-tissue and inter-organ crosstalk (factors outside of the joint organ system that may signal to the joint).[103] Current spatial transcriptomics techniques produce unique molecular identifiers (UMIs) in a capture radius of ~55 μm, and approaches have been developed to identify putative cell-cell communication data [e.g., communication analysis by optimal transport][104] (Fig. 3). Given the relatively recent development of spatial-omics approaches, we will briefly highlight how these technologies have been applied to OA and other rheumatic diseases to illustrate potential utility of these techniques.

While approaches have been established to assess the spatial immune cell milieu, they have yet to be used in the OA context, despite established protocols for formalin fixed, paraffin embedded and frozen tissues.[105] In psoriatic arthritis, spatial transcriptomics was used to identify molecular signatures that separate early and severe disease states.[106] Synovial biopsies from RA patients were evaluated using spatial transcriptomics to identify changes in B cells


Fig. 3

Osteoarthritis and Cartilage

Spatial transcriptomics pipeline. Fixed or frozen tissue is embedded in paraffin or OCT as required by the specific protocol (1). Next, using a kit from 10×, nanostring, or others, the tissue is prepared, for example, by removing paraffin using xylenes, dried, and typically kept cold until the assay is performed. The same slide or serial slide is used for staining by hematoxylin and eosin which will later be used to resolve spatial information with sequencing data. The tissue is transferred to a barcoded slide using protocols and kits provided by manufacturers (2). The barcoded slide is imaged and either the full genome or a limited dataset is sequenced, pending which spatial technique is selected (3). Then, gene expression data are generated (4), and data is analyzed and processed (5) to determine whole section and tissue specific changes in gene expression (6).

concordant with alterations in tissue architecture, helping disentangle whether plasma cells are present before or after tissue remodeling.[107]

Spatial metabolomic information can also be observed using matrix-assisted laser desorption ionization (MALDI)-MS imaging. Rocha and colleagues used this approach to characterize lipodomic profiles of synovial tissues in OA vs. RA and psoriatic arthritis. This approach yielded characteristic lipidomic profiles from OA patients that may help identify pathophysiological mechanisms in OA.[108] MALDI-MS images have been integrated with label-free proteomics to illustrate that OA cartilage of subjects with and without type 2 diabetes have differential lipid and protein profiles.[109] For example, these spatial analyses revealed that patients with type 2 diabetes who were OA negative had more phosphatidylcholine and sphingomyelin species, compared to patients with type 2 diabetes and OA who had more lysolipids.[109] This observation confirms that phosphatidylcholine and sphingomyelin species are key elements of healthy cartilage.[109] Furthermore, phospholipid content differed in superficial and deep zones of cartilage, which would have not been detectable without these spatial analyses. Opportunities to assess spatial proteomics in OA have been reviewed elsewhere.[110] As emerging approaches reach single-cell resolutions (UMIs of 5–10 μm) and are capable of multi-omic measures, we are uniquely positioned to integrate these technologies to overcome the lack of spatial information in musculoskeletal crosstalk research as exemplified by the methods showcasing single cell-resolution transcriptomic information utilizing image-seq.[111]

Researchers have delineated roadmaps for building cell atlases involving single and spatial multi-omic assessments, which outline a vision and strategic direction for investigation as these technologies advance.[112] It would be useful to develop similar strategies and goals to integrate such technologies to bridge the gap between limited spatial information in OA joint tissues and answering open questions about OA phenotypes as a collective research community.

Multi-omics

Most individual omic studies in OA have focused on a single technology. However, the integration of multiple omics technologies on biological samples from the same individual may help to uncover links between transcriptomic, proteomic and metabolomic signatures, among other technologies, that could aid in defining novel molecular profiles of individual OA patients, generating patient-specific endotypes (Fig. 4). A current multi-omics approach is integrating scRNA-seq with spatial sequencing, using deconvolution approaches to define cell populations spatially.[113] In addition, scATAC-seq and scRNA-seq can be performed to


Fig. 4

Osteoarthritis and Cartilage

Multi-omics integration for identification of OA endophenotypes. Combining sociodemographic, clinical, and omic-technology data can inform of OA patient endophenotypes through statistical analyses, integrative computational analyses, and artificial intelligence. Of note, multiple endotype-phenotype combinations are possible using this approach. Uncovering OA endophenotypes can enable precision medicine approaches for treatment and enhanced therapeutic discovery.

identify open chromatin regions linked to RNA gene expression,[114] with computational approaches used to predict transcription factors able to bind accessible DNA regions and regulate transcriptomic programs.

Several challenges exist for multi-omics analyses including differences in initial data handling, individual omic data heterogeneity and noise, computational constraints, and data interpretations.[115,116] However, various approaches have been proposed to investigate multi-omics data including correlation analyses,[117] network-based approaches,[117–119] supervised or unsupervised machine learning,[120] among others.[121,122] Tools and visualization portals can aid in multi-omics analysis and interpretation.[122,123]

In addition to generating multi-omics OA endotypes, integration with patient sociodemographic and clinical variables (phenotypes) to generate endophenotypes will be critical (Fig. 4). Not surprisingly, there are associations between signatures of omic datasets and OA risk factors,[124–128] as well as omic signatures and measures of OA disease,[42,129–133] suggesting linkages across OA disease, omic patterns, and patient phenotypes. Integrating patient-level characteristics with biological omic data may be helpful in unraveling the heterogeneity of OA patients and therapeutic outcomes. Some tools have incorporated the ability to investigate multi-omics and clinical variables together to uncover consensus clusters,[134] essentially endophenotypes. Although currently undefined, multiple endotypes may underlie individual patient phenotypes, aiding in our understanding of OA patient heterogeneity and possibly explaining differences in OA outcomes based on phenotype alone. Determining how endophenotypes relate to disease prognosis and therapeutic efficacy will be vital to improve outcomes for patients with OA.

Conclusions

Since their inception, the utilization of transcriptomics, proteomics and metabolomics technologies has made remarkable strides in advancing our understanding of molecular, cellular, and tissue contributions to OA disease pathology and joint homeostasis. As omic technologies have progressed, so too has the breadth and depth of information collected regarding transcriptomes, proteomes and metabolomes in OA.

The next goals of omic research in OA appear clear: 1) further technological improvements and novel additions to omic methodologies; 2) expansion of omic datasets to include OA patient phenotypes and the incorporation of spatial information; and 3) analysis of multi-omics datasets from various platforms and patient-level data to define OA patient endophenotypes. These goals are poised to enhance our understanding of OA heterogeneity, improve the integration of specific OA endophenotypes into study designs, and ultimately improve study outcomes and interpretations for more effective OA precision medicine approaches.

References

1. Vina ER, Kwoh CK. Epidemiology of osteoarthritis: literature update. Curr Opin Rheumatol 2018;30:160–7.
2. Allen KD, Thoma LM, Golightly YM. Epidemiology of osteoarthritis. Osteoarthritis Cartilage 2022;30:184–95.
3. Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review. Osteoarthritis Cartilage 2017;25:1926–41.
4. Dell'Isola A, Allan R, Smith SL, Marreiros SS, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord 2016;17, 425.
5. Batushansky A, Zhu S, Komaravolu RK, South S, Mehta-D'souza P, Griffin TM. Fundamentals of OA. An initiative of Osteoarthritis and Cartilage. Obesity and metabolic factors in OA. Osteoarthritis Cartilage 2022;30:501–15.
6. Angelini F, Widera P, Mobasheri A, Blair J, Struglics A, Uebelhoer M, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann Rheum Dis 2022;81:666–75.
7. Velculescu VE, Zhang L, Zhou W, Vogelstein J, Basrai MA, Bassett Jr. DE, et al. Characterization of the yeast transcriptome. Cell 1997;88:243–51.
8. Godovac-Zimmermann J. 8th Siena meeting. From genome to proteome: integration and proteome completion. Expert Rev Proteomics 2008;5:769–73.
9. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol 1998;16:373–8.
10. Fiehn O. Metabolomics–the link between genotypes and phenotypes. Plant Mol Biol 2002;48:155–71.
11. Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L. Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum 2001;44:2777–89.

12. Sato T, Konomi K, Yamasaki S, Aratani S, Tsuchimochi K, Yokouchi M, et al. Comparative analysis of gene expression profiles in intact and damaged regions of human osteoarthritic cartilage. Arthritis Rheum 2006;54:808–17.

13. Aigner T, Fundel K, Saas J, Gebhard PM, Haag J, Weiss T, et al. Large-scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis. Arthritis Rheum 2006;54:3533–44.

14. Karlsson C, Dehne T, Lindahl A, Brittberg M, Pruss A, Sittinger M, et al. Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis. Osteoarthritis Cartilage 2010;18:581–92.

15. Ramos YF, den Hollander W, Bovee JV, Bomer N, van der Breggen R, Lakenberg N, et al. Genes involved in the osteoarthritis process identified through genome wide expression analysis in articular cartilage; the RAAK study. PLoS One 2014;9, e103056.

16. Geyer M, Grassel S, Straub RH, Schett G, Dinser R, Grifka J, et al. Differential transcriptome analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology. Osteoarthritis Cartilage 2009;17:328–35.

17. Appleton CT, Pitelka V, Henry J, Beier F. Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum 2007;56:1854–68.

18. Gardiner MD, Vincent TL, Driscoll C, Burleigh A, Bou-Gharios G, Saklatvala J, et al. Transcriptional analysis of micro-dissected articular cartilage in post-traumatic murine osteoarthritis. Osteoarthritis Cartilage 2015;23:616–28.

19. Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan M, Ferguson C, et al. Disease progression and phasic changes in gene expression in a mouse model of osteoarthritis. PLoS One 2013;8, e54633.

20. Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan MF, Ferguson CM, et al. Microarray analysis reveals age-related differences in gene expression during the development of osteoarthritis in mice. Arthritis Rheum 2012;64:705–17.

21. Mobasheri A, Kapoor M, Ali SA, Lang A, Madry H. The future of deep phenotyping in osteoarthritis: how can high throughput omics technologies advance our understanding of the cellular and molecular taxonomy of the disease? Osteoarthr Cartil Open 2021;3, 100144.

22. Fernandez-Tajes J, Soto-Hermida A, Vazquez-Mosquera ME, Cortes-Pereira E, Mosquera A, Fernandez-Moreno M, et al. Genome-wide DNA methylation analysis of articular chondrocytes reveals a cluster of osteoarthritic patients. Ann Rheum Dis 2014;73:668–77.

23. Soul J, Dunn SL, Anand S, Serracino-Inglott F, Schwartz JM, Boot-Handford RP, et al. Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage. Ann Rheum Dis 2018;77:423.

24. Steinberg J, Southam L, Fontalis A, Clark MJ, Jayasuriya RL, Swift D, et al. Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis. Ann Rheum Dis 2021;80:1070–4.

25. Yuan C, Pan Z, Zhao K, Li J, Sheng Z, Yao X, et al. Classification of four distinct osteoarthritis subtypes with a knee joint tissue transcriptome atlas. Bone Res 2020;8, 38.

26. Ji Q, Zheng Y, Zhang G, Hu Y, Fan X, Hou Y, et al. Single-cell RNA-seq analysis reveals the progression of human osteoarthritis. Ann Rheum Dis 2019;78:100–10.

27. Chou CH, Jain V, Gibson J, Attarian DE, Haraden CA, Yohn CB, et al. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. Sci Rep 2020;10, 10868.

28. Lv Z, Han J, Li J, Guo H, Fei Y, Sun Z, et al. Single cell RNA-seq analysis identifies ferroptotic chondrocyte cluster and reveals TRPV1 as an anti-ferroptotic target in osteoarthritis. EBioMedicine 2022;84, 104258.

29. Sebastian A, McCool JL, Hum NR, Murugesh DK, Wilson SP, Christiansen BA, et al. Single-cell RNA-Seq reveals transcriptomic heterogeneity and post-traumatic osteoarthritis-associated early molecular changes in mouse articular chondrocytes. Cells 2021;10:1462.

30. Sunkara V, Heinz GA, Heinrich FF, Durek P, Mobasheri A, Mashreghi MF, et al. Combining segmental bulk- and single-cell RNA-sequencing to define the chondrocyte gene expression signature in the murine knee joint. Osteoarthritis Cartilage 2021;29:905–14.

31. Sanchez-Lopez E, Coras R, Torres A, Lane NE, Guma M. Synovial inflammation in osteoarthritis progression. Nat Rev Rheumatol 2022;18:258–75.

32. Remst D, Blom A, Vitters E, Bank R, van den Berg W, Blaney Davidson E, et al. Gene expression analysis of murine and human osteoarthritis synovium reveals elevation of transforming growth factor β–responsive genes in osteoarthritis-related fibrosis. Arthritis Rheumatol 2014;66:647–56.

33. Lambert C, Dubuc JE, Montell E, Vergés J, Munaut C, Noël A, et al. Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane. Arthritis Rheumatol 2014;66:960–8.

34. Del Rey MJ, Usategui A, Izquierdo E, Cañete JD, Blanco FJ, Criado G, et al. Transcriptome analysis reveals specific changes in osteoarthritis synovial fibroblasts. Ann Rheum Dis 2012;71:275–80.

35. Steinberg J, Southam L, Fontalis A, Clark MJ, Jayasuriya RL, Swift D, et al. Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis. Ann Rheum Dis 2021;80:1070–4.

36. Philpott HT, Birmingham TB, Fiset B, Walsh LA, Coleman MC, Séguin CA, et al. Tensile strain and altered synovial tissue metabolism in human knee osteoarthritis. Sci Rep 2022;12, 17367.

37. Wood MJ, Leckenby A, Reynolds G, Spiering R, Pratt AG, Rankin KS, et al. Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients. JCI Insight 2019;4, e125325.

38. Bergman RF, Lammlin L, Junginger L, Farrell E, Goldman S, Darcy R, et al. Sexual dimorphism of the synovial transcriptome underpins greater PTOA disease severity in male mice following joint injury. Osteoarthritis Cartilage 2023. S1063-4584(23)00915-9, In press.

39. Mizoguchi F, Slowikowski K, Wei K, Marshall JL, Rao DA, Chang SK, et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun 2018;9, 789.

40. Buechler MB, Pradhan RN, Krishnamurty AT, Cox C, Calviello AK, Wang AW, et al. Cross-tissue organization of the fibroblast lineage. Nature 2021;593:575–9.

41. Chou C-H, Jain V, Gibson J, Attarian DE, Haraden CA, Yohn CB, et al. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. Sci Rep 2020;10, 10868.

42. Nanus DE, Badoume A, Wijesinghe SN, Halsey AM, Hurley P, Ahmed Z, et al. Synovial tissue from sites of joint pain in knee osteoarthritis patients exhibits a differential phenotype with distinct fibroblast subsets. EBioMedicine 2021;72, 103618.

43. Knights AJ, Farrell EC, Ellis OM, Lammlin L, Junginger LM, Rzeczycki PM, et al. Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis. Ann Rheum Dis 2023;82:272–82.

44. Collins FL, Roelofs AJ, Symons RA, Kania K, Campbell E, Collie-Duguid ES, et al. Taxonomy of fibroblasts and progenitors in the synovial joint at single-cell resolution. Ann Rheum Dis 2023;82:428–37.

45. Aso K, Shahtaheri SM, Hill R, Wilson D, McWilliams DF, Walsh DA. Associations of symptomatic knee osteoarthritis with histopathologic features in subchondral bone. Arthritis Rheumatol 2019;71:916–24.

46. Muratovic D, Findlay DM, Cicuttini FM, Wluka AE, Lee YR, Kuliwaba JS. Bone matrix microdamage and vascular changes characterize bone marrow lesions in the subchondral bone of knee osteoarthritis. Bone 2018;108:193–201.

47. Geurts J, Patel A, Hirschmann MT, Pagenstert GI, Muller-Gerbl M, Valderrabano V, et al. Elevated marrow inflammatory cells and osteoclasts in subchondral osteosclerosis in human knee osteoarthritis. J Orthop Res 2016;34:262–9.

48. Walsh DA, McWilliams DF, Turley MJ, Dixon MR, Franses RE, Mapp PI, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 2010;49:1852–61.

49. Zanetti M, Bruder E, Romero J, Hodler J. Bone marrow edema pattern in osteoarthritic knees: correlation between MR imaging and histologic findings. Radiology 2000;215:835–40.

50. Hopwood B, Tsykin A, Findlay DM, Fazzalari NL. Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther 2007;9:R100.

51. Delgado-Calle J, Fernandez AF, Sainz J, Zarrabeitia MT, Sanudo C, Garcia-Renedo R, et al. Genome-wide profiling of bone reveals differentially methylated regions in osteoporosis and osteoarthritis. Arthritis Rheum 2013;65:197–205.

52. Kuttapitiya A, Assi L, Laing K, Hing C, Mitchell P, Whitley G, et al. Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation. Ann Rheum Dis 2017;76:1764–73.

53. Chou CH, Wu CC, Song IW, Chuang HP, Lu LS, Chang JH, et al. Genome-wide expression profiles of subchondral bone in osteoarthritis. Arthritis Res Ther 2013;15, R190.

54. Tuerlings M, van Hoolwerff M, Houtman E, Suchiman E, Lakenberg N, Mei H, et al. RNA sequencing reveals interacting key determinants of osteoarthritis acting in subchondral bone and articular cartilage: identification of IL11 and CHADL as attractive treatment targets. Arthritis Rheumatol 2021;73:789–99.

55. Yan H, Jin C, Han L, Sicheng W, Qirong Z, Hao Z, et al. Single-cell RNA-sequencing analysis reveals the molecular mechanism of subchondral bone cell heterogeneity in the development of osteoarthritis. RMD Open 2022;8, e002314.

56. Lodewyckx L, Cailotto F, Thysen S, Luyten FP, Lories RJ. Tight regulation of wingless-type signaling in the articular cartilage - subchondral bone biomechanical unit: transcriptomics in Frzb-knockout mice. Arthritis Res Ther 2012;14:R16.

57. Kaya S, Bailey KN, Schurman CA, Evans DS, Alliston T. Bone-cartilage crosstalk informed by aging mouse bone transcriptomics and human osteoarthritis genome-wide association studies. Bone Rep 2023;18, 101647.

58. Zhang R, Fang H, Chen Y, Shen J, Lu H, Zeng C, et al. Gene expression analyses of subchondral bone in early experimental osteoarthritis by microarray. PLoS One 2012;7, e32356.

59. Shabestari M, Shabestari YR, Landin MA, Pepaj M, Cleland TP, Reseland JE, et al. Altered protein levels in bone marrow lesions of hip osteoarthritis: analysis by proteomics and multiplex immunoassays. Int J Rheum Dis 2020;23:788–99.

60. Wang Y, Wu C, Tao J, Zhao D, Jiang X, Tian W. Differential proteomic analysis of tibial subchondral bone from male and female guinea pigs with spontaneous osteoarthritis. Exp Ther Med 2021;21, 633.

61. Bundgaard L, Ahrman E, Malmstrom J, Auf dem Keller U, Walters M, Jacobsen S. Effective protein extraction combined with data independent acquisition analysis reveals a comprehensive and quantifiable insight into the proteomes of articular cartilage and subchondral bone. Osteoarthritis Cartilage 2022;30:137–46.

62. Roller BL, Monibi FA, Stoker AM, Kuroki K, Bal BS, Cook JL. Characterization of knee meniscal pathology: correlation of gross, histologic, biochemical, molecular, and radiographic measures of disease. J Knee Surg 2015;28:175–82.

63. Brophy RH, Zhang B, Cai L, Wright RW, Sandell LJ, Rai MF. Transcriptome comparison of meniscus from patients with and without osteoarthritis. Osteoarthritis Cartilage 2018;26:422–32.

64. Jiang Z, Du X, Wen X, Li H, Zeng A, Sun H, et al. Whole-transcriptome sequence of degenerative meniscus cells unveiling diagnostic markers and therapeutic targets for osteoarthritis. Front Genet 2021;12, 754421.

65. Sun H, Wen X, Li H, Wu P, Gu M, Zhao X, et al. Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration. Ann Rheum Dis 2020;79:408–17.

66. Ruiz-Romero C, Carreira V, Rego I, Remeseiro S, Lopez-Armada MJ, Blanco FJ. Proteomic analysis of human osteoarthritic chondrocytes reveals protein changes in stress and glycolysis. Proteomics 2008;8:495–507.

67. Hsueh MF, Khabut A, Kjellstrom S, Onnerfjord P, Kraus VB. Elucidating the molecular composition of cartilage by proteomics. J Proteome Res 2016;15:374–88.

68. Grandi FC, Baskar R, Smeriglio P, Murkherjee S, Indelli PF, Amanatullah DF, et al. Single-cell mass cytometry reveals cross-talk between inflammation-dampening and inflammation-amplifying cells in osteoarthritic cartilage. Sci Adv 2020;6, eaay5352.

69. Sahu N, Grandi FC, Bhutani N. A single-cell mass cytometry platform to map the effects of preclinical drugs on cartilage homeostasis. JCI Insight 2022;7, e160702.

70. Stevens AL, Wishnok JS, White FM, Grodzinsky AJ, Tannenbaum SR. Mechanical injury and cytokines cause loss of cartilage integrity and upregulate proteins associated with catabolism, immunity, inflammation, and repair. Mol Cell Proteomics 2009;8:1475–89.

71. Lourido L, Calamia V, Mateos J, Fernandez-Puente P, Fernandez-Tajes J, Blanco FJ, et al. Quantitative proteomic profiling of human articular cartilage degradation in osteoarthritis. J Proteome Res 2014;13:6096–106.

72. Balakrishnan L, Nirujogi RS, Ahmad S, Bhattacharjee M, Manda SS, Renuse S, et al. Proteomic analysis of human osteoarthritis synovial fluid. Clin Proteomics 2014;11, 6.

73. Ali N, Turkiewicz A, Hughes V, Folkesson E, Tjornstand J, Neuman P, et al. Proteomics profiling of human synovial fluid suggests increased protein interplay in early-osteoarthritis (OA) that is lost in late-stage OA. Mol Cell Proteomics 2022;21, 100200.

74. Zhou K, Li YJ, Soderblom EJ, Reed A, Jain V, Sun S, et al. A "best-in-class" systemic biomarker predictor of clinically relevant knee osteoarthritis structural and pain progression. Sci Adv 2023;9, eabq5095.

75. Fuehrer J, Pichler KM, Fischer A, Giurea A, Weinmann D, Altmann F, et al. N-Glycan profiling of chondrocytes and fibroblast-like synoviocytes: towards functional glycomics in osteoarthritis. Proteomics Clin Appl 2021;15, e2000057.

76. Luo Y, Wu Z, Chen S, Luo H, Mo X, Wang Y, et al. Protein N-glycosylation aberrations and glycoproteomic network alterations in osteoarthritis and osteoarthritis with type 2 diabetes. Sci Rep 2022;12, 6977.

77. Dong Y, Wang P, Zhang M, Xiao L, Yang Y, Wang B, *et al.* Phosphoproteomics reveals the BRAF-ERK1/2 axis as an important pathogenic signaling node in cartilage degeneration. Osteoarthritis Cartilage 2022;30:1443–54.

78. Wang Y, Li Y, Khabut A, Chubinskaya S, Grodzinsky AJ, Onnerfjord P. Quantitative proteomics analysis of cartilage response to mechanical injury and cytokine treatment. Matrix Biol 2017;63:11–22.

79. Fernandez-Puente P, Gonzalez-Rodriguez L, Calamia V, Picchi F, Lourido L, Camacho-Encina M, *et al.* Analysis of endogenous peptides released from osteoarthritic cartilage unravels novel pathogenic markers. Mol Cell Proteomics 2019;18:2018–28.

80. Bhutada S, Li L, Willard B, Muschler G, Piuzzi N, Apte SS. Forward and reverse degradomics defines the proteolytic landscape of human knee osteoarthritic cartilage and the role of the serine protease HtrA1. Osteoarthritis Cartilage 2022;30:1091–102.

81. Styrkarsdottir U, Lund SH, Saevarsdottir S, Magnusson MI, Gunnarsdottir K, Norddahl GL, *et al.* The CRTAC1 protein in plasma is associated with osteoarthritis and predicts progression to joint replacement: a large-scale proteomics scan in Iceland. Arthritis Rheumatol 2021;73:2025–34.

82. Szilagyi IA, Vallerga CL, Boer CG, Schiphof D, Ikram MA, Bierma-Zeinstra SMA, *et al.* Plasma proteomics identifies CRTAC1 as a biomarker for osteoarthritis severity and progression. Rheumatology (Oxford) 2023;62:1286–95.

83. Styrkarsdottir U, Lund SH, Thorleifsson G, Saevarsdottir S, Gudbjartsson DF, Thorsteinsdottir U, *et al.* Cartilage acidic protein 1 in plasma associates with prevalent osteoarthritis and predicts future risk as well as progression to joint replacements: results from the UK Biobank Resource. Arthritis Rheumatol 2023;75:544–52.

84. Borel M, Pastoureau P, Papon J, Madelmont JC, Moins N, Maublant J, *et al.* Longitudinal profiling of articular cartilage degradation in osteoarthritis by high-resolution magic angle spinning ^{1}H NMR spectroscopy: experimental study in the meniscectomized guinea pig model. J Proteome Res 2009;8:2594–600.

85. Hugle T, Kovacs H, Heijnen IA, Daikeler T, Baisch U, Hicks JM, *et al.* Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. Clin Exp Rheumatol 2012;30:240–5.

86. Loeser RF, Pathmasiri W, Sumner SJ, McRitchie S, Beavers D, Saxena P, *et al.* Association of urinary metabolites with radiographic progression of knee osteoarthritis in overweight and obese adults: an exploratory study. Osteoarthritis Cartilage 2016;24:1479–86.

87. Zhai G, Wang-Sattler R, Hart DJ, Arden NK, Hakim AJ, Illig T, *et al.* Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. Ann Rheum Dis 2010;69:1227–31.

88. Gierman LM, Wopereis S, van El B, Verheij ER, Werff-van der Vat BJ, Bastiaansen-Jenniskens YM, *et al.* Metabolic profiling reveals differences in concentrations of oxylipins and fatty acids secreted by the infrapatellar fat pad of donors with end-stage osteoarthritis and normal donors. Arthritis Rheum 2013;65:2606–14.

89. Wu X, Liyanage C, Plan M, Stark T, McCubbin T, Barrero RA, *et al.* Dysregulated energy metabolism impairs chondrocyte function in osteoarthritis. Osteoarthritis Cartilage 2023;31:613–26.

90. McCutchen CN, Zignego DL, June RK. Metabolic responses induced by compression of chondrocytes in variable-stiffness microenvironments. J Biomech 2017;64:49–58.

91. Hahn AK, Rawle RA, Bothner B, Prado Lopes EB, Griffin TM, June RK. In vivo mechanotransduction: effect of acute exercise on the metabolomic profiles of mouse synovial fluid. Osteoarthr Cartil Open 2022;4, 100228.

92. Hahn AK, Batushansky A, Rawle RA, Prado Lopes EB, June RK, Griffin TM. Effects of long-term exercise and a high-fat diet on synovial fluid metabolomics and joint structural phenotypes in mice: an integrated network analysis. Osteoarthritis Cartilage 2021;29:1549–63.

93. Hahn AK, Wallace CW, Welhaven HD, Brooks E, McAlpine M, Christiansen BA, *et al.* The microbiome mediates epiphyseal bone loss and metabolomic changes after acute joint trauma in mice. Osteoarthritis Cartilage 2021;29:882–93.

94. Chen D, Su X, Wang N, Li Y, Yin H, Li L, *et al.* Chemical isotope labeling LC-MS for monitoring disease progression and treatment in animal models: plasma metabolomics study of osteoarthritis rat model. Sci Rep 2017;7, 40543.

95. de Visser HM, Mastbergen SC, Ravipati S, Welsing PMJ, Pinto FC, Lafeber F, *et al.* Local and systemic inflammatory lipid profiling in a rat model of osteoarthritis with metabolic dysregulation. PLoS One 2018;13, e0196308.

96. Kim S, Hwang J, Kim J, Ahn JK, Cha HS, Kim KH. Metabolite profiles of synovial fluid change with the radiographic severity of knee osteoarthritis. Joint Bone Spine 2017;84:605–10.

97. Carlson AK, Rawle RA, Wallace CW, Brooks EG, Adams E, Greenwood MC, *et al.* Characterization of synovial fluid metabolomic phenotypes of cartilage morphological changes associated with osteoarthritis. Osteoarthritis Cartilage 2019;27:1174–84.

98. Werdyani S, Liu M, Zhang H, Sun G, Furey A, Randell EW, *et al.* Endotypes of primary osteoarthritis identified by plasma metabolomics analysis. Rheumatology (Oxford) 2021;60:2735–44.

99. Rockel JS, Layeghifard M, Rampersaud YR, Perruccio AV, Mahomed NN, Davey JR, *et al.* Identification of a differential metabolite-based signature in patients with late-stage knee osteoarthritis. Osteoarthr Cartil Open 2022;4, 100258.

100. Costello CA, Hu T, Liu M, Zhang W, Furey A, Fan Z, *et al.* Metabolomics signature for non-responders to total joint replacement surgery in primary osteoarthritis patients: the Newfoundland Osteoarthritis Study. J Orthop Res 2020;38: 793–802.

101. Murillo-Saich JD, Coras R, Meyer R, Llorente C, Lane NE, Guma M. Synovial tissue metabolomic profiling reveal biomarkers of synovial inflammation in patients with osteoarthritis. Osteoarthr Cartil Open 2022;4, 100295.

102. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 2012;64:1697–707.

103. Collins KH, Lenz KL, Pollitt EN, Ferguson D, Hutson I, Springer LE, *et al.* Adipose tissue is a critical regulator of osteoarthritis. Proc Natl Acad Sci U S A 2021;118, e2021096118.

104. Cang Z, Zhao Y, Almet AA, Stabell A, Ramos R, Plikus MV, *et al.* Screening cell-cell communication in spatial transcriptomics via collective optimal transport. Nat Methods 2023;20:218–28.

105. Black S, Phillips D, Hickey JW, Kennedy-Darling J, Venkataraaman VG, Samusik N, *et al.* CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat Protoc 2021;16:3802–35.

106. Castillo RL, Sidhu I, Dolgalev I, Chu T, Prystupa A, Subudhi I, *et al.* Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems. Sci Immunol 2023;8, eabq7991.

107. Hardt U, Carlberg K, Af Klint E, Sahlstrom P, Larsson L, van Vollenhoven A, *et al.* Integrated single cell and spatial transcriptomics reveal autoreactive differentiated B cells in joints of early rheumatoid arthritis. Sci Rep 2022;12, 11876.

108. Rocha B, Cillero-Pastor B, Ruiz-Romero C, Paine MRL, Canete JD, Heeren RMA, *et al.* Identification of a distinct lipidomic profile in the osteoarthritic synovial membrane by mass spectrometry imaging. Osteoarthritis Cartilage 2021;29:750–61.

109. Eveque-Mourroux MR, Emans PJ, Boonen A, Claes BSR, Bouwman FG, Heeren RMA, *et al.* Heterogeneity of lipid and

protein cartilage profiles associated with human osteoarthritis with or without type 2 diabetes mellitus. J Proteome Res 2021;20:2973–82.

110. Eveque-Mourroux MR, Rocha B, Barre FPY, Heeren RMA, Cillero-Pastor B. Spatially resolved proteomics in osteoarthritis: state of the art and new perspectives. J Proteomics 2020;215, 103637.

111. Haase C, Gustafsson K, Mei S, Yeh SC, Richter D, Milosevic J, et al. Image-seq: spatially resolved single-cell sequencing guided by in situ and in vivo imaging. Nat Methods 2022;19:1622–33.

112. Caetano AJ, Human Cell Atlas O, Craniofacial B, Sequeira I, Byrd KM. A roadmap for the human oral and craniofacial cell atlas. J Dent Res 2022;101:1274–88.

113. Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet 2023;24:494–515.

114. Reyes M, Billman K, Hacohen N, Blainey PC. Simultaneous profiling of gene expression and chromatin accessibility in single cells. Adv Biosyst 2019;3, 1900065.

115. Krassowski M, Das V, Sahu SK, Misra BB. State of the field in multi-omics research: from computational needs to data mining and sharing. Front Genet 2020;11, 610798.

116. Picard M, Scott-Boyer MP, Bodein A, Perin O, Droit A. Integration strategies of multi-omics data for machine learning analysis. Comput Struct Biotechnol J 2021;19:3735–46.

117. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol 2017;18, 83.

118. Zhou G, Li S, Xia J. Network-based approaches for multi-omics integration. Methods Mol Biol 2020;2104:469–87.

119. Agamah FE, Bayjanov JR, Niehues A, Njoku KF, Skelton M, Mazandu GK, et al. Computational approaches for network-based integrative multi-omics analysis. Front Mol Biosci 2022;9, 967205.

120. Reel PS, Reel S, Pearson E, Trucco E, Jefferson E. Using machine learning approaches for multi-omics data analysis: a review. Biotechnol Adv 2021;49, 107739.

121. Jendoubi T. Approaches to integrating metabolomics and multi-omics data: a primer. Metabolites 2021;11:184.

122. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights 2020;14, 1177932219899051.

123. Briere G, Darbo E, Thebault P, Uricaru R. Consensus clustering applied to multi-omics disease subtyping. BMC Bioinformatics 2021;22, 361.

124. Senol O, Gundogdu G, Gundogdu K, Miloglu FD. Investigation of the relationships between knee osteoarthritis and obesity via untargeted metabolomics analysis. Clin Rheumatol 2019;38: 1351–60.

125. Rockel JS, Zhang W, Shestopaloff K, Likhodii S, Sun G, Furey A, et al. A classification modeling approach for determining metabolite signatures in osteoarthritis. PLoS One 2018;13, e0199618.

126. Li C, Zheng Z. Males and females have distinct molecular events in the articular cartilage during knee osteoarthritis. Int J Mol Sci 2021;22, 7876.

127. Yang Y, You X, Cohen JD, Zhou H, He W, Li Z, et al. Sex differences in osteoarthritis pathogenesis: a comprehensive study based on bioinformatics. Med Sci Monit 2020;26, e923331.

128. Tardif G, Pare F, Gotti C, Roux-Dalvai F, Droit A, Zhai G, et al. Mass spectrometry-based proteomics identify novel serum osteoarthritis biomarkers. Arthritis Res Ther 2022;24, 120.

129. Costello CA, Rockel JS, Liu M, Gandhi R, Perruccio AV, Rampersaud YR, et al. Individual participant data meta-analysis of metabolomics on sustained knee pain in primary osteoarthritis patients. Rheumatology (Oxford) 2023;62:1964–71.

130. Ali SA, Espin-Garcia O, Wong AK, Potla P, Pastrello C, McIntyre M, et al. Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort. Ther Adv Musculoskelet Dis 2022;14. 1759720X221082917.

131. Ali SA, Gandhi R, Potla P, Keshavarzi S, Espin-Garcia O, Shestopaloff K, et al. Sequencing identifies a distinct signature of circulating microRNAs in early radiographic knee osteoarthritis. Osteoarthritis Cartilage 2020;28:1471–81.

132. Bratus-Neuenschwander A, Castro-Giner F, Frank-Bertoncelj M, Aluri S, Fucentese SF, Schlapbach R, et al. Pain-associated transcriptome changes in synovium of knee osteoarthritis patients. Genes (Basel) 2018;9.

133. Montesino-Goicolea S, Meng L, Rani A, Huo Z, Foster TC, Fillingim RB, et al. Enrichment of genomic pathways based on differential DNA methylation profiles associated with knee osteoarthritis pain. Neurobiol Pain 2022;12, 100107.

134. Tyler SR, Chun Y, Ribeiro VM, Grishina G, Grishin A, Hoffman GE, et al. Merged affinity network association clustering: joint multi-omic/clinical clustering to identify disease endotypes. Cell Rep 2021;35, 108975.